Mexican Social Security Institute (IMSS) director Mikel Arriola announced the Institute’s work with pharmaceuticals on a joint venture model. Mexican authorities will invest only on innovative treatments with scientific evidence of efficiency. Should the treatments be unsuccessful, pharmaceuticals would cover part of the costs.

Negotiations are ongoing between the IMSS and the Mexican Asociation of Pharmaceutical Research (AMIF). The goal is to settle on a joint venture model with agreements between pharmaceutical companies and IMSS which have concrete benefits in health care.

Should the medication acquired by the government result inefficient or below standard, pharmaceuticals will give back part of the investment to the State. Sources indicate both parties will sign the agreements voluntarily.